The green tea extract component DNMT inhibitor EGCG and Polyphenon E were used in two different phase 2 clinical trials (NCT00917735 and NCT00676793) to investigate the effect of green tea extract on breast cancer progression. Here, DNMT1 is linked to breast cancer.